{"id":"W4379470548","doi":"10.1182/bloodadvances.2022009575","title":"Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Okanagan University College; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"Servier; Italfarmaco; Celltrion; Incyte; BeiGene; Pharmacyclics; MEI Pharma; Regeneron Pharmaceuticals; FibroGen; Gilead Sciences; Bayer HealthCare; Sanofi; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Cilag; Astellas Pharma; TG Therapeutics; Amgen; Pfizer; GlaxoSmithKline","keywords":"Refractory (planetary science); Medicine; Multicenter study; Open label; Oncology; Internal medicine; Cancer research; Clinical trial; Biology; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002014181,0.001532146,0.001605953,0.0003522253,0.0003612233,0.0007175455,0.0007624816,0.0009113016,0.001582849],"category_scores_gemma":[0.0006193976,0.0004680041,0.0009895383,0.0002318725,0.0007215909,0.0007179497,0.0002790212,0.001885653,0.0004561361],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006313915,"about_ca_system_score_gemma":0.001195685,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005299043,"about_ca_topic_score_gemma":0.001178755,"domain_scores_codex":[0.9996116,0.0001965464,0.0000201972,0.00005476113,0.0000412619,0.00007576901],"domain_scores_gemma":[0.999529,0.00006530592,0.0001101297,0.00004947677,0.00003215203,0.0002139976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5130706,0.1912974,0.01858562,0.0006943329,0.001576004,0.000970018,0.0006325529,0.002523387,0.1414176,0.0003329223,0.003662124,0.1252374],"study_design_scores_gemma":[0.3859349,0.5791304,0.02232033,0.00003102085,0.0003976095,0.0007626323,0.00009142349,0.002126069,0.006881066,0.0001184432,0.002159469,0.00004668801],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980122,0.0004889124,0.0002404898,0.00009063142,0.00002385003,0.0006535795,0.0002208008,0.00003035995,0.0002392605],"genre_scores_gemma":[0.9931472,0.0009387573,0.001588275,0.0004980331,0.0001548143,0.001721104,0.001259192,0.0000184115,0.0006741183],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002014181,"threshold_uncertainty_score":0.01065212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02035521279004659,"score_gpt":0.3210531474843764,"score_spread":0.3006979346943298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}